Latest Conference Articles

Pharmacists play a critical and evolving role in sports medicine by optimizing medication use, guiding safe supplementation, and delivering personalized, prevention-focused care to support athlete performance and overall health.

How pharmacists are uniquely positioned to support athlete health, performance, recovery, and regulatory compliance through medication expertise and interdisciplinary care.

Artificial intelligence, real-world data, and patient voices reshape pharmacovigilance, helping pharmacists spot risks faster and strengthen life cycle drug safety.

Erin Dorval, PharmD, highlights the pharmacist’s role in safe athlete pain management, emphasizing appropriate NSAID use, alternative therapies, and emerging trends like personalized care and wearable-driven performance optimization.

Ahead of the Sports Pharmacy Summit, Erin Dorval, PharmD, highlights the pharmacist’s role in optimizing athlete performance and recovery through safe medication use, careful supplement evaluation, and a holistic, risk-minimizing approach to care.

Brandon Welch, PharmD, highlights the expanding role of sports pharmacists in medication safety, anti-doping, and personalized athlete care.

At APhA 2026, Callan Bleick, PharmD, MSc, laid out a stark picture of antimicrobial resistance, vaccine-preventable disease resurgence, and updated treatment guidelines.

A FINEARTS-HF subgroup analysis shows patients with HFpEF and comorbid sleep apnea face a 43% higher adjusted cardiovascular risk.

In a phase 2a trial, the oral NLRP3 inhibitor VTX3232 significantly reduced systemic and liver inflammation markers—including hsCRP and IL-6—independent of weight loss, suggesting a promising new approach to lowering cardiovascular risk in patients with obesity.

A phase 3 trial found that the oral PCSK9 inhibitor enlicitide significantly outperformed existing oral therapies in lowering LDL cholesterol.

Kelly Gable, PharmD, shares how empathy, presence, and practical guidance can transform patient experiences beyond the medication plan.

Alex Wolff, PharmD, BCOP, FHOPA, explains how patient populations, delivery models, and safety risks shape real-world implementation.

Evolocumab produced a 31% relative risk reduction in major cardiovascular events.

From a pipeline exploding with oral and injectable options to emerging evidence in liver disease, substance use disorder, and kidney disease, Emily Eddy, PharmD, laid out the full scope of incretin therapy's expanding reach at APhA2026.

New data show that pharmacist-led interventions in independent community pharmacies can move the needle on A1C, blood pressure, and stroke risk, even in rural and underserved settings.

SCOUT-HCM trial showed that mavacamten reduced left ventricular outflow tract obstruction in adolescents with obstructive HCM.

The trial's success offers the first robust evidence for targeted pharmacologic intervention in adolescent oHCM.

The CADENCE trial showed that sotatercept reduced pulmonary vascular resistance and improved right ventricular function in CPC-PH.

Finerenone consistently reduces heart failure events and cardiovascular death regardless of ischemic heart disease history, according to the FINEARTS-HF trial.

The KARDINAL trial demonstrated meaningful angiotensinogen reduction with a novel monthly injectable therapy.

For decades, the medical community has operated under a reactive model for the most potent cholesterol-lowering drugs, largely reserving them for secondary prevention.

At APhA 2026, Damika Walker, PharmD, RPh, argued that closing stubbornly low adult vaccination rates requires a shift in how pharmacists approach every patient encounter.

The findings emphasize that when it comes to the complex machinery of human blood pressure, more drug is not always better.

With updated recommendations for adults aged 50 and older, pharmacy teams are uniquely positioned to bridge gaps in care through community engagement and proactive clinical assessments.